Clinical Trials Logo

Erdheim-Chester Disease clinical trials

View clinical trials related to Erdheim-Chester Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03794297 Withdrawn - Clinical trials for Erdheim-Chester Disease

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Start date: January 4, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well dabrafenib and trametinib work in treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02298634 Withdrawn - Splenomegaly Clinical Trials

Biomarker for Farber Disease (BioFarber)

BioFarber
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood